Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Mersana shares climb as BTIG upgrades to buy with $6 target

EditorNatashya Angelica
Published 02/28/2024, 04:05 PM
Updated 02/28/2024, 04:05 PM
© Reuters.

On Wednesday, Mersana Therapeutics Inc . (NASDAQ:MRSN) received an upgrade from a BTIG analyst, moving from a Neutral to a Buy rating, with a new price target set at $6.00. The upgrade is based on the potential for upcoming catalysts this year to significantly de-risk the company's Dolasynthen platform and its lead antibody-drug conjugate (ADC), XMT-1660.

The analyst highlighted the importance of forthcoming clinical data expected to be released at the European Society of Gynaecological Oncology (ESGO) conference, scheduled from March 7-10. The data includes results from the Uplift trial for UpRi, set to be presented on March 10, and from the Phase 1 trial for XMT-1592, which will be disclosed on March 8. Both drugs, now discontinued, target NaPi2b and carry the Dolalock payload, but differ in their design technologies.

UpRi, which was developed using Dolaflexin technology, is a heterogeneous mixture of ADCs, whereas XMT-1592 is a single-species ADC designed using the Dolasynthen platform, which is also utilized for XMT-1660. The analyst expressed the belief that the data from these two drugs could answer critical questions regarding the safety of the Dolasynthen platform, especially whether XMT-1660 can be dosed at levels that are both safe and effective.

The key toxicities associated with UpRi that have raised concerns are pneumonitis and bleeding. The forthcoming data is expected to clarify if these issues have been addressed in the Dolasynthen platform, thereby potentially improving the safety profile of XMT-1660.

The BTIG analyst's comments suggest that the success of the Dolasynthen platform and XMT-1660 could hinge on the ability to deliver meaningful doses to patients without incurring the concerning toxicities observed with UpRi. The upcoming clinical readouts are therefore seen as pivotal for Mersana's progress in developing its ADC technologies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.